Coronavirus sequence chest stimulates frustration

on
featured image

Science‘s COVID-19 reporting is supported by the Heising-Simons Structure


Embedded Image

GISAID information can assist researchers construct visualizations such as this one of the coronavirus genome.

IMAGE: MARTIN KRZYWINSKI/SCIENCE SOURCE

In December 2020, software application developer Angie Hinrichs at the University of California, Santa Cruz (UCSC), gotten access to a labor-saving data feed from GISAID, a nonprofit database of viral sequences consisting of those of the pandemic coronavirus, SARS-CoV-2. She desired GISAID’s information so she might display mutations on UCSC’s coronavirus Genome Internet browser. That tool ties any position in the infection’ nearly 30,000- letter genome to other scientific information, much as Google Maps reveals filling station and dining establishments near addresses.

With more than 700,000 genomes from more than 160 countries, GISAID is without a doubt the world’s largest database of SARS-CoV-2 sequences. Access to the free, nonprofit repository has actually ended up being essential to Hinrichs and thousands of other scientists and public health firms tracking the infection’ amazingly fast development.

However instead of getting a direct data feed, Hinrichs lost her current access to two conveniently packaged GISAID files that are the next best thing. She emailed GISAID repeatedly advocating restored access, however hasn’t gotten it. Since December, she has actually had to download GISAID’s sequences 10,000 at a time, without any access to most of the metadata unless she looks at each of the 10,000 sequences individually. As a result, she states, “My [phylogenetic] trees that utilize GISAID information are falling back.”

Hinrichs’s experience is not unique. A dozen researchers spoke to Science raising grievances about their interactions with GISAID. They reported a nontransparent procedure of gaining access, unexplained disruptions when gain access to was won, and phone harangues or threatening legal letters when they got on the incorrect side of GISAID’s rigorous guidelines against resharing information. Many researchers who voiced criticisms declined to be identified for fear of losing GISAID access. They state that even as they race to study coronavirus evolution, they are strolling on eggshells around their chief information provider.

” I am so tired of being terrified all the time, of being terrified that if I take an action wrong I will lose access to the data that I base my research study on,” states one scientist who decreases to be determined. “[GISAID] has that sword hanging over any researcher that deals with SARS-CoV-2.”

In a statement, GISAID stated, “Any person who signs up with GISAID and accepts the GISAID terms of usage will be given gain access to qualifications. … On uncommon events, GISAID has found it needed to briefly suspend access credentials to protect the GISAID sharing mechanism.”

Both fans and critics highlight that GISAID has actually supplied an important service during the pandemic, collecting a lot more coronavirus sequences than open-access databases like the United States’s GenBank (see graphic, below). Even critics note that information are a lot easier to publish to GISAID than to open-access repositories, and that GISAID quickly curates series.

” GISAID has done a remarkable job. They truly have revolutionized access to all these data,” states David Haussler, a computational biologist at UCSC who is Hinrichs’s manager. “We really, truly want give them credit for what they have accomplished.”

Many scientists trace what they deem a secretive, managing organizational culture to GISAID’s co-creator and head, former Time Warner studio executive Peter Bogner. GISAID “has a personality behind it that is fiercely protective of the organization [and] very insulted if somebody else … is applauded for SARS-CoV-2 information,” Hinrichs says.

Bogner has actually said he invested a number of million dollars to introduce GISAID in2008 Its objective was to open access to then-restricted bird flu series, and to safeguard researchers in non-Western countries versus having their data scooped for publication or earnings by requiring users to credit and attempt to work together with depositors ( Science, 25 August 2006, p. 1026 and 16 February 2007, p. 923).

GISAID, which stands for the Worldwide Effort on Sharing All Influenza Data, is today supported by personal donors, federal governments, and nonprofits and is based in Germany; it states it remains “ independent of government and business interests.”

In its declaration to Science, GISAID said scientists deposit to its database since they “are confident that their rights will be protected.” Without GISAID, “We would now remain in genuine problem, since it’s been successful in building confidence in SARS-CoV-2 genomic information sharing in nations around the globe,” states GISAID co-founder Nancy Cox, now retired from the U.S. Centers for Disease Control and Prevention.

But critics grumble about GISAID’s restraints on gain access to, chief among them its prohibition on resharing of its information. Its contract for access to the direct information feed likewise requires candidates to use only GISAID information in their sites and tools, in addition to only GISAID-approved stress names.

Other researchers state the gain access to procedure itself is opaque. Brooks Miner, an evolutionary ecologist at Ithaca College, contacted GISAID on 2 February intending to get a data feed for a lay-friendly site mapping the frequency of coronavirus versions. He got a phone call with instructions from a guy who refused to identify himself except as “a GISAID representative” and whose identity he still does not know. “I began calling him Mr. GISAID,” Miner states. (GISAID stated it does not have a policy of not identifying its agents.)

Puzzled, Miner contacted other GISAID users and discovered they resided in fear of losing gain access to. “I understood individuals doing phenomenal innovative science carry this worry that their profession might be ruined on an impulse by this faceless company,” Miner states.

Miner was granted GISAID gain access to last week however says he fears losing it since of his criticisms. “I’m speaking out anyhow due to the fact that I believe the way GISAID runs is flawed,” he says.

Other researchers say they have actually received threatening letters from GISAID attorneys. Early in the pandemic, Hinrichs pulled GISAID information from another company, Nextstrain, and mistakenly failed to credit GISAID, triggering what she calls an “ominous” missive from a law practice directed to Haussler. “This was a brand-new experience for us,” Hinrichs states. “We are used to talking with scientists, not hearing from attorneys.” She added GISAID credits to the web browser.

In its statement, GISAID said, “GISAID has actually never ever found it required to begin a legal action versus a participant. … We generally have the ability to come to a speedy and amicable resolution of any problems.” GISAID says it has withdrawed access for only one user in the past year, since they “would not abide by GISAID’s terms of usage.”

Some researchers say they have gotten call lecturing them on the virtues of GISAID and the defects of public-access databases.” GISAID sees every series sent to GenBank as a battle lost,” another researcher says.

Kelly Oakeson, chief sequencing researcher at the Utah Public Health Lab, which depends on GISAID data to track coronavirus variations in his state, recalls Bogner telephoning him last year for a technical matter and then advising him not to deposit sequences in GenBank. He” truly wanted to know …’ What possible great could come of that? You’ve got it in one place, why do you need it in both? ‘”

GISAID rejects disparaging GenBank or preventing users from depositing in it or other open-access databases.

In January, researchers pressed back in an open letter advising researchers to deposit series in GenBank, the European Nucleotide Archive( ENA), and Japan’s DDBJ, open-access databases that permit users to access sequences anonymously and share data easily. “The ideal setup is entirely open access, “to speed research study, states signatory Guy Cochrane, head of the ENA.” Having a minimal group managing [access] would never be an advantage.”

GISAID countered in its statement that the letter “successfully calls for data to be shared anonymously and without any protection for the data contributors.”

Some users state they have only had good experiences with GISAID. “I have actually gotten much more assistance from GISAID than from any federal government firm,” states Jeremy Kamil, a virologist at Louisiana State University Health, Shreveport, and senior author on a recent preprint that recognized seven new SARS-CoV-2 versions in the United States. He says he discovers GISAID’s international, 24/ 7 staff responsive and valuable.

However others see much room for improvement. They want a right of appeal if they lose GISAID gain access to and a transparent view of how GISAID is governed. They want to open a discussion about ways GISAID might relax its data-sharing requirements during the pandemic, without risking their gain access to by raising the subject.

Miner would likewise like to see a less territorial technique: “Aren’t we simply attempting to do good work that’s useful in the pandemic?”

Learn More

http://covid19globalcases.com/coronavirus-sequence-chest-stimulates-frustration/

Comments

Post a Comment